The system combines multiple Beckman technologies including microbioreactor, liquid handling, antibody titer and cell health measurements into one platform
Biomedical company Beckman Coulter Life Sciences has launched the Cydem VT Automated Clone Screening System, a microbioreactor platform for automated top clone screening.
“Our Cydem VT Automated Clone Screening System offers a revolution to expedite critical research therapies for illnesses, including autoimmune diseases and many types of cancer,” said Beckman product manager Dr Sebastian Hofzumahaus.
The system combines multiple Beckman technologies including microbioreactor, liquid handling, antibody titer and cell health measurements into one platform.
The Cydem VT system automates the screening of clones while collecting data on cell growth and productivity, reducing manual responsibilities by up to 90% in one experiment.
Operators can leave the system running automatically for three days at a time, while online, non-invasive pH, dissolved oxygen (DO) and biomass measurements provide continuous control over cultivation parameters.
Using Beckman’s Vi-CELL BLU Cell Viability Analyser, the system offers regular updates of cell count and viability, providing labs with more reliable clones than traditional methods.
The system’s integrated bioreactor module can cultivate 96 clones in 24-deep-well bioreactor plates in parallel, while providing online monitoring of pH, DO, and biomass. This fosters better cultivation conditions that are closer to biomanufacturing production.
The system reduces manual screening steps as well as the overall time to market for biologic drug discovery and monoclonal antibody-based therapeutics. The screening platform is particularly useful in cell line development of CHO cell lines producing monoclonal antibodies (mAbs).
“We heard the concerns about selecting poor productivity clones and understood the critical need to develop an easy-to-use solution that consistently identifies the best clones,” said Hofzumahaus.
“Through providing early answers and better cultivation conditions, we are able to ensure greater accuracy with fewer steps to reduce the risk of bad clones to help laboratories discover their next big breakthrough even faster and positively impact human health.”
Earlier this month, Beckman partnered with biotechnology company 10x Genomics to launch a solution to automate single cell gene expression workflows.
